Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Advancing Biomarker Development Through Convergent Engagement: Summary Report of the 2nd International Danube Symposium on Biomarker Development, Molecular Imaging and Applied Diagnostics; March 14-16, 2018; Vienna, Austria.

Lim MS, Beyer T, Babayan A, Bergmann M, Brehme M, Buyx A, Czernin J, Egger G, Elenitoba-Johnson KSJ, Gückel B, Jačan A, Haslacher H, Hicks RJ, Kenner L, Langanke M, Mitterhauser M, Pichler BJ, Salih HR, Schibli R, Schulz S, Simecek J, Simon J, Soares MO, Stelzl U, Wadsak W, Zatloukal K, Zeitlinger M, Hacker M.

Mol Imaging Biol. 2019 May 2. doi: 10.1007/s11307-019-01361-2. [Epub ahead of print]

PMID:
31049831
2.

Combined PET/MRI: Global Warming-Summary Report of the 6th International Workshop on PET/MRI, March 27-29, 2017, Tübingen, Germany.

Bailey DL, Pichler BJ, Gückel B, Antoch G, Barthel H, Bhujwalla ZM, Biskup S, Biswal S, Bitzer M, Boellaard R, Braren RF, Brendle C, Brindle K, Chiti A, la Fougère C, Gillies R, Goh V, Goyen M, Hacker M, Heukamp L, Knudsen GM, Krackhardt AM, Law I, Morris JC, Nikolaou K, Nuyts J, Ordonez AA, Pantel K, Quick HH, Riklund K, Sabri O, Sattler B, Troost EGC, Zaiss M, Zender L, Beyer T.

Mol Imaging Biol. 2018 Feb;20(1):4-20. doi: 10.1007/s11307-017-1123-5.

3.

18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start.

Seith F, Forschner A, Schmidt H, Pfannenberg C, Gückel B, Nikolaou K, la Fougère C, Garbe C, Schwenzer N.

Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):95-101. doi: 10.1007/s00259-017-3813-2. Epub 2017 Aug 22.

PMID:
28831583
4.

Impact of 18F-FDG-PET/CT on surgical management in patients with advanced melanoma: an outcome based analysis.

Forschner A, Olthof SC, Gückel B, Martus P, Vach W, la Fougère C, Nikolaou K, Keim U, Eigentler TK, Garbe C, Pfannenberg C.

Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1312-1318. doi: 10.1007/s00259-017-3674-8. Epub 2017 Mar 18.

PMID:
28315947
5.

Combined PET/MRI: from Status Quo to Status Go. Summary Report of the Fifth International Workshop on PET/MR Imaging; February 15-19, 2016; Tübingen, Germany.

Bailey DL, Pichler BJ, Gückel B, Barthel H, Beer AJ, Botnar R, Gillies R, Goh V, Gotthardt M, Hicks RJ, Lanzenberger R, la Fougere C, Lentschig M, Nekolla SG, Niederdraenk T, Nikolaou K, Nuyts J, Olego D, Riklund KÅ, Signore A, Schäfers M, Sossi V, Suminski M, Veit-Haibach P, Umutlu L, Wissmeyer M, Beyer T.

Mol Imaging Biol. 2016 Oct;18(5):637-50. doi: 10.1007/s11307-016-0993-2.

6.

HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy.

Peper JK, Bösmüller HC, Schuster H, Gückel B, Hörzer H, Roehle K, Schäfer R, Wagner P, Rammensee HG, Stevanović S, Fend F, Staebler A.

Oncoimmunology. 2015 Jul 1;5(5):e1065369. doi: 10.1080/2162402X.2015.1065369. eCollection 2016 May.

7.

[Simultaneous whole-body PET-MRI in pediatric oncology : More than just reducing radiation?].

Gatidis S, Gückel B, la Fougère C, Schmitt J, Schäfer JF.

Radiologe. 2016 Jul;56(7):622-30. doi: 10.1007/s00117-016-0122-x. Review. German.

PMID:
27306199
8.

Combined PET/MRI: Multi-modality Multi-parametric Imaging Is Here: Summary Report of the 4th International Workshop on PET/MR Imaging; February 23-27, 2015, Tübingen, Germany.

Bailey DL, Pichler BJ, Gückel B, Barthel H, Beer AJ, Bremerich J, Czernin J, Drzezga A, Franzius C, Goh V, Hartenbach M, Iida H, Kjaer A, la Fougère C, Ladefoged CN, Law I, Nikolaou K, Quick HH, Sabri O, Schäfer J, Schäfers M, Wehrl HF, Beyer T.

Mol Imaging Biol. 2015 Oct;17(5):595-608. doi: 10.1007/s11307-015-0886-9. Review.

PMID:
26286794
9.

Patient comfort during positron emission tomography/magnetic resonance and positron emission tomography/computed tomography examinations: subjective assessments with visual analog scales.

Gückel B, Gatidis S, Enck P, Schäfer J, Bisdas S, Pfannenberg C, Schwenzer N.

Invest Radiol. 2015 Oct;50(10):726-32. doi: 10.1097/RLI.0000000000000177.

PMID:
26039772
10.

Combined PET/MR: The Real Work Has Just Started. Summary Report of the Third International Workshop on PET/MR Imaging; February 17-21, 2014, Tübingen, Germany.

Bailey DL, Antoch G, Bartenstein P, Barthel H, Beer AJ, Bisdas S, Bluemke DA, Boellaard R, Claussen CD, Franzius C, Hacker M, Hricak H, la Fougère C, Gückel B, Nekolla SG, Pichler BJ, Purz S, Quick HH, Sabri O, Sattler B, Schäfer J, Schmidt H, van den Hoff J, Voss S, Weber W, Wehrl HF, Beyer T.

Mol Imaging Biol. 2015 Jun;17(3):297-312. doi: 10.1007/s11307-014-0818-0.

11.

Simultaneous whole-body PET/MR imaging in comparison to PET/CT in pediatric oncology: initial results.

Schäfer JF, Gatidis S, Schmidt H, Gückel B, Bezrukov I, Pfannenberg CA, Reimold M, Ebinger M, Fuchs J, Claussen CD, Schwenzer NF.

Radiology. 2014 Oct;273(1):220-31. doi: 10.1148/radiol.14131732. Epub 2014 May 31.

PMID:
24877983
12.

Combined PET/MR: Where are we now? Summary report of the second international workshop on PET/MR imaging April 8-12, 2013, Tubingen, Germany.

Bailey DL, Barthel H, Beuthin-Baumann B, Beyer T, Bisdas S, Boellaard R, Czernin J, Drzezga A, Ernemann U, Franzius C, Gückel B, Handgretinger R, Hartenbach M, Hellwig D, Nadel H, Nekolla SG, Pfluger T, Pichler BJ, Quick HH, Sabri O, Sattler B, Schäfer J, Schick F, Siegel BA, Schlemmer HP, Schwenzer NF, van den Hoff J, Veit-Haibach P, Wehrl HF.

Mol Imaging Biol. 2014 Jun;16(3):295-310. doi: 10.1007/s11307-014-0725-4. Review.

PMID:
24668195
13.

Summary report of the First International Workshop on PET/MR imaging, March 19-23, 2012, Tübingen, Germany.

Bailey DL, Barthel H, Beyer T, Boellaard R, Gückel B, Hellwig D, Herzog H, Pichler BJ, Quick HH, Sabri O, Scheffler K, Schlemmer HP, Schwenzer NF, Wehrl HF.

Mol Imaging Biol. 2013 Aug;15(4):361-71. doi: 10.1007/s11307-013-0623-1.

14.

MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-κB and TGF-β signaling pathways.

Keklikoglou I, Koerner C, Schmidt C, Zhang JD, Heckmann D, Shavinskaya A, Allgayer H, Gückel B, Fehm T, Schneeweiss A, Sahin O, Wiemann S, Tschulena U.

Oncogene. 2012 Sep 13;31(37):4150-63. doi: 10.1038/onc.2011.571. Epub 2011 Dec 12.

PMID:
22158050
15.

Simvastatin reduces tumor cell adhesion to human peritoneal mesothelial cells by decreased expression of VCAM-1 and β1 integrin.

Wagner BJ, Löb S, Lindau D, Hörzer H, Gückel B, Klein G, Glatzle J, Rammensee HG, Brücher BL, Königsrainer A.

Int J Oncol. 2011 Dec;39(6):1593-600. doi: 10.3892/ijo.2011.1167. Epub 2011 Aug 18.

PMID:
21874229
16.

Peptide microarrays for the profiling of cytotoxic T-lymphocyte activity using minimum numbers of cells.

Hoff A, Bagû AC, André T, Roth G, Wiesmüller KH, Gückel B, Brock R.

Cancer Immunol Immunother. 2010 Sep;59(9):1379-87. doi: 10.1007/s00262-010-0867-4. Epub 2010 May 29.

17.

Antigen loading of dendritic cells with apoptotic tumor cell-preparations is superior to that using necrotic cells or tumor lysates.

Inzkirweli N, Gückel B, Sohn C, Wallwiener D, Bastert G, Lindner M.

Anticancer Res. 2007 Jul-Aug;27(4B):2121-9.

18.

Pre-existing T-cell immunity against mucin-1 in breast cancer patients and healthy volunteers.

Gückel B, Rentzsch C, Nastke MD, Marmé A, Gruber I, Stevanović S, Kayser S, Wallwiener D.

J Cancer Res Clin Oncol. 2006 Apr;132(4):265-74. Epub 2005 Dec 22.

PMID:
16374613
19.

A CD80-transfected human breast cancer cell variant induces HER-2/neu-specific T cells in HLA-A*02-matched situations in vitro as well as in vivo.

Gückel B, Stumm S, Rentzsch C, Marmé A, Mannhardt G, Wallwiener D.

Cancer Immunol Immunother. 2005 Feb;54(2):129-40. Epub 2004 Sep 9.

PMID:
15365776
20.
21.

Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells.

Rentzsch C, Kayser S, Stumm S, Watermann I, Walter S, Stevanoviç S, Wallwiener D, Gückel B.

Clin Cancer Res. 2003 Oct 1;9(12):4376-86.

22.

Tumor-associated antigen profiling in breast and ovarian cancer: mRNA, protein or T cell recognition?

Kayser S, Watermann I, Rentzsch C, Weinschenk T, Wallwiener D, Gückel B.

J Cancer Res Clin Oncol. 2003 Jul;129(7):397-409. Epub 2003 Jun 26.

PMID:
12836015
23.

[CD80-modified tumor cell lines: implications for cell-based vaccinations in breast cancer patients].

Gückel B, Stumm S, Kayser S, Rentzsch C, Gruber I, Marmé A, Huober J, Meuer SC, Wallwiener D.

Zentralbl Gynakol. 2002 Dec;124(12):566-73. German.

PMID:
12822070
24.

Effect of tamoxifen and 2-methoxyestradiol alone and in combination on human breast cancer cell proliferation.

Seeger H, Diesing D, Gückel B, Wallwiener D, Mueck AO, Huober J.

J Steroid Biochem Mol Biol. 2003 Feb;84(2-3):255-7.

PMID:
12711011
25.

CD40-expressing carcinoma cells induce down-regulation of CD40 ligand (CD154) and impair T-cell functions.

Batrla R, Linnebacher M, Rudy W, Stumm S, Wallwiener D, Gückel B.

Cancer Res. 2002 Apr 1;62(7):2052-7.

26.

A MAGE-A1 HLA-A A*0201 epitope identified by mass spectrometry.

Pascolo S, Schirle M, Gückel B, Dumrese T, Stumm S, Kayser S, Moris A, Wallwiener D, Rammensee HG, Stevanovic S.

Cancer Res. 2001 May 15;61(10):4072-7.

27.
28.

Interleukin-12 requires initial CD80-mediated T-cell activation to support immune responses toward human breast and ovarian carcinoma.

Gückel B, Meyer GC, Rudy W, Batrla R, Meuer SC, Bastert G, Wallwiener D, Moebius U.

Cancer Gene Ther. 1999 May-Jun;6(3):228-37.

29.

Induction of antigen-specific T cells by allogeneic CD80 transfected human carcinoma cells.

Meyer GC, Moebius U, Rudy W, Batrla R, Meuer SC, Wallwiener D, Gückel B.

Adv Exp Med Biol. 1998;451:195-202. No abstract available.

PMID:
10026872
31.
32.

Construction of immunogenic tumor cell surfaces by somatic gene transfer.

Meuer SC, Gückel B, Lindauer M, Rudy W, Moebius U.

Recent Results Cancer Res. 1998;144:78-85. Review. No abstract available.

PMID:
9304710
33.

Differential function of CD80- and CD86-transfected human melanoma cells in the presence of IL-12 and IFN-gamma.

Rudy W, Gückel B, Siebels M, Lindauer M, Meuer SC, Moebius U.

Int Immunol. 1997 Jun;9(6):853-60.

PMID:
9199968
34.

[Immunoscintigraphy of breast cancer xenografts. 99m-Tc-labeled anti-mucin monoclonal antibodies BM-7 and 12H12].

Brümmendorf TH, Kaul S, Schuhmacher J, Baum RP, Klivény G, Matys R, Eichler A, Gückel B, Beldermann F, Bastert G.

Nuklearmedizin. 1995 Oct;34(5):197-202. German.

PMID:
7479094
35.

CD80-transfected human breast and ovarian tumor cell lines: improved immunogenicity and induction of cytolytic CD8+ T lymphocytes.

Gückel B, Lindauer M, Rudy W, Habicht A, Siebels M, Kaul S, Bastert G, Meuer SC, Moebius U.

Cytokines Mol Ther. 1995 Sep;1(3):211-21.

PMID:
9384677
36.

Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.

Schirrmacher V, Schild HJ, Gückel B, von Hoegen P.

Immunol Cell Biol. 1993 Aug;71 ( Pt 4):311-26.

PMID:
7901150
37.

Anti-CD2 antibodies induce T cell unresponsiveness in vivo.

Gückel B, Berek C, Lutz M, Altevogt P, Schirrmacher V, Kyewski BA.

J Exp Med. 1991 Nov 1;174(5):957-67.

38.

Murine CD2 mediates cellular immune responses in vivo.

Bromberg JS, Chavin KD, Lau HT, Altevogt P, Kyewski BA, Guckel B, Naji A, Barker CF.

Transplant Proc. 1991 Feb;23(1 Pt 1):856-8. No abstract available.

PMID:
1671310
39.

Anti-CD2 monoclonal antibodies alter cell-mediated immunity in vivo.

Bromberg JS, Chavin KD, Altevogt P, Kyewski BA, Guckel B, Naji A, Barker CF.

Transplantation. 1991 Jan;51(1):219-25.

PMID:
1670971

Supplemental Content

Loading ...
Support Center